Vacuum Erection Devices: How They Work, How They Compare to ED Pills, and Who Should Use One

What Is a Vacuum Erection Device and How Does It Work?

A vacuum erection device consists of a plastic cylinder placed over the penis, a hand or battery pump that removes air to create negative pressure, and a constriction ring slid from the base of the cylinder onto the penile shaft once erection is achieved. The negative pressure causes venous engorgement of the corpora cavernosa and corpus spongiosum. Blood inflow is largely passive rather than arterially driven, which is why VED-assisted erections are sometimes cooler and more distal than spontaneous erections.

The FDA classifies prescription VEDs as Class II devices under 21 CFR 876.3400 [1]. Over-the-counter "novelty" pumps sold without a prescription do not carry the same quality or pressure-limiting standards, so the clinical literature almost exclusively studies prescription-grade devices.

The physiological basis for using VEDs as rehabilitation tools, not only rescue devices, rests on oxygenation cycling. Cavernous smooth muscle requires periodic oxygenation to prevent fibrosis. Daily or every-other-day VED use after radical prostatectomy may reduce corporal fibrosis and preserve penile length, a finding supported by a randomized study of 109 men by Raina et al. (2006) published in Urology, in which nightly VED use beginning within 30 days of surgery produced significantly better erectile function scores at 9 months than observation alone [2].

The constriction ring must be removed after 30 minutes. Leaving it longer risks ischemia, petechiae, and in rare cases ischemic necrosis [3].

How Effective Are VEDs? Key Efficacy Data

Satisfaction rates of 68 to 80% are frequently cited, but the study designs behind those numbers matter. A 1996 meta-analysis by Cookson and Nadig covering 1,517 men across multiple device types found a combined patient-partner satisfaction rate of approximately 68% at 12 months [4]. Later data from Turner et al. (1991) reported that 80% of men achieved intercourse-quality erections in controlled laboratory settings, though long-term adherence dropped to roughly 50 to 60% by 18 months due to mechanical inconvenience [5].

Men with diabetic vasculogenic ED, spinal cord injury, and post-prostatectomy states show the most consistent benefit because their ED is often refractory to oral agents alone. In a prospective cohort of 40 men with spinal cord injury at T6 or below, 72.5% achieved penetration-suitable rigidity with VED versus 37.5% with sildenafil 100 mg monotherapy [6]. That is not a head-to-head randomized trial, but the gap is clinically meaningful.

Penile rehabilitation after radical prostatectomy deserves separate emphasis. A 2006 RCT by Raina et al. (N=74) showed that men randomized to early VED use recovered Sexual Health Inventory for Men (SHIM) scores of 14.5 vs. 10.5 at 6 months compared to controls (P<0.05) [2]. A 2010 RCT by Köhler et al. (N=109) demonstrated that nightly VED use prevented loss of stretched penile length over 12 months, a common morbidity after prostatectomy [7].

Efficacy data are weakest for psychogenic ED, where PDE5 inhibitors work well and VEDs add mechanical friction without clear benefit over pills.

Sildenafil (Viagra): The Reference Standard for On-Demand Oral ED Treatment

Sildenafil, sold as Viagra and now widely available as generic sildenafil, was the first oral PDE5 inhibitor approved by the FDA in March 1998 [8]. It selectively inhibits phosphodiesterase type 5, raising cyclic GMP in cavernous smooth muscle and allowing arterial inflow in response to sexual stimulation.

Approved doses are 25 mg, 50 mg, and 100 mg taken 30 to 60 minutes before activity. Onset is 30 to 60 minutes and duration is approximately 4 to 6 hours in most men. A high-fat meal delays absorption by up to 60 minutes and reduces peak plasma concentration by roughly 29%, which is why sildenafil is taken on an empty or light stomach [9].

The landmark NEJM trial by Goldstein et al. (1998) in 532 men showed that sildenafil produced successful intercourse in 69% of attempts vs. 22% for placebo (P<0.001) [10]. The International Index of Erectile Function (IIEF) erectile function domain score improved by a mean of 7.1 points over placebo.

Common adverse effects include headache (16%), flushing (10%), dyspepsia (7%), and transient blue-tinged or hazy vision from mild PDE6 inhibition in the retina [9]. Sildenafil is absolutely contraindicated with nitrates (nitroglycerin, isosorbide dinitrate, isosorbide mononitrate) and with soluble guanylate cyclase stimulators such as riociguat due to the risk of severe hypotension [8].

Men who need or want daily coverage, not on-demand dosing, typically find sildenafil's 4, 6-hour window limiting. That is where tadalafil's pharmacokinetics become relevant.

Tadalafil (Cialis): The Long-Acting Option and Its Daily Dosing Advantage

Tadalafil's half-life of 17.5 hours separates it from every other approved PDE5 inhibitor [11]. The FDA approved tadalafil in November 2003 under the brand name Cialis [12]. As-needed dosing is 10 mg or 20 mg taken at least 30 minutes before activity, with an effective window of up to 36 hours. The 2.5 mg and 5 mg once-daily formulations provide continuous background coverage that removes the need to time a dose around anticipated sex.

A phase III trial published in European Urology (Porst et al., 2003, N=348) found that tadalafil 20 mg improved IIEF erectile function domain scores by 8.6 points over placebo, with 75% of intercourse attempts successful vs. 32% for placebo [13]. The daily 5 mg dose in the LVHRD trial (N=1,054) produced comparable domain score improvements of 5.8 points, with additional benefit on lower urinary tract symptoms associated with benign prostatic hyperplasia, an indication sildenafil does not carry [14].

Tadalafil shares sildenafil's nitrate contraindication. Myalgia and back pain, caused by PDE11 inhibition in skeletal muscle, occur in about 5 to 6% of users and are more specific to tadalafil than to sildenafil [12]. Food does not meaningfully affect tadalafil absorption, a practical advantage over sildenafil.

Compared to a VED, daily tadalafil 5 mg offers convenience without the mechanical steps or ring-related discomfort. However, tadalafil still requires intact neurovascular signaling for adequate arterial inflow. Men with severe cavernous arterial insufficiency or complete nerve injury may get insufficient response from tadalafil 20 mg and should consider combining it with a VED or moving to intracavernosal injection therapy.

Vardenafil (Levitra, Staxyn): High Potency and the Sublingual Option

Vardenafil hydrochloride, marketed as Levitra (oral tablet) and Staxyn (orally disintegrating tablet), received FDA approval in August 2003 [15]. Its PDE5 selectivity ratio is approximately 10-fold higher than sildenafil, meaning it binds PDE5 more tightly at equivalent concentrations. Approved tablet doses are 5 mg, 10 mg, and 20 mg; Staxyn is available as a 10 mg orally disintegrating tablet that dissolves on the tongue without water.

A key Phase III RCT (Goldstein et al., 2003, Journal of Urology, N=805) demonstrated that vardenafil 10 mg and 20 mg produced IIEF domain score improvements of 6.4 and 7.1 points over placebo, with successful intercourse rates of 65% and 72% at the highest dose vs. 35% for placebo (P<0.001) [16]. Onset is typically 25 to 60 minutes, and duration is approximately 4 to 5 hours, broadly similar to sildenafil.

Vardenafil shows modest QTc prolongation at supratherapeutic doses and is therefore contraindicated with Class IA antiarrhythmics (quinidine, procainamide) and Class III antiarrhythmics (amiodarone, sotalol) [15]. Men with a QTc >450 ms at baseline should use it with caution. A high-fat meal reduces vardenafil Cmax by approximately 18 to 20%, less of a concern than with sildenafil but still worth noting.

In the context of VED comparisons, vardenafil offers no meaningful mechanical rehabilitation benefit. It requires arterial response to stimulation just as sildenafil does. The Staxyn formulation may appeal to men who dislike swallowing tablets, but pharmacologically it behaves identically to standard vardenafil 10 mg.

Avanafil (Stendra): The Fastest Oral PDE5 Inhibitor

Avanafil, approved by the FDA in April 2012 as Stendra, has the fastest onset of the four approved oral ED agents [17]. In pharmacokinetic studies, time to maximum plasma concentration (Tmax) is approximately 30 to 45 minutes, and meaningful clinical effect has been observed as early as 15 minutes in a subset of men in the VIVUS key trial.

That trial (Goldstein et al., 2012, Journal of Sexual Medicine, N=646) showed that avanafil 100 mg and 200 mg produced IIEF domain improvements of 7.22 and 8.84 points over placebo, with successful intercourse rates of 57% and 59% vs. 27% for placebo at 12 weeks [18]. A responder analysis found that 64% of men who had failed prior PDE5 therapy achieved successful intercourse with avanafil 200 mg.

Avanafil has greater PDE5 selectivity than sildenafil or vardenafil, which translates to a lower rate of visual side effects (approximately 1 to 2% vs. 3 to 11% with sildenafil) [17]. Flushing and headache rates are similar across class. Duration of action is 6 to 12 hours. Approved doses are 50 mg, 100 mg, and 200 mg taken 15 to 30 minutes before activity.

For men who want spontaneity without a VED's mechanical setup, avanafil 100 to 200 mg is the most practical oral option. However, like all PDE5 inhibitors, it requires sufficient penile arterial supply and neural signaling. Men with post-prostatectomy ED or severe vascular disease may still get superior results from a VED, either alone or combined with avanafil.

VED vs. PDE5 Inhibitors: A Direct Comparison

The choice between a VED and an oral PDE5 inhibitor is not a binary one. It depends on vascular anatomy, comorbidities, concurrent medications, and patient preference.

When a VED is preferred or necessary: Men taking long-acting nitrates for coronary artery disease cannot use any PDE5 inhibitor safely. A VED has no systemic hemodynamic effect and carries no nitrate interaction. Men who have had nerve-sparing or non-nerve-sparing radical prostatectomy and do not yet have spontaneous erections benefit from early VED rehabilitation while oral agents may be temporarily ineffective. Men with complete cavernous arterial occlusion may achieve mechanical erection with a VED when oral agents fail entirely.

When PDE5 inhibitors are preferred: Psychogenic ED, mild to moderate vasculogenic ED with intact neural signaling, and men who find the mechanical steps of a VED inhibiting to spontaneity are better served by oral agents. Tadalafil 5 mg daily, in particular, requires no planning and produces sustained background PDE5 inhibition that enables erections to occur naturally with stimulation.

Combination therapy evidence: A 2005 RCT by Raina et al. (N=91 post-prostatectomy men) showed that men using a VED plus sildenafil 50 mg had higher SHIM scores at 12 months (mean 16.3) than men using sildenafil alone (mean 12.6) or VED alone (mean 13.1) (P<0.05) [19]. Combining a VED with a PDE5 inhibitor may be the most effective oral-plus-mechanical strategy in neurovasculogenic cases.

Side effect profiles compared: VEDs do not cause headache, flushing, dyspepsia, myalgia, or nasal congestion. Their adverse effects are mechanical: petechiae, bruising, ejaculatory discomfort due to ring compression, a cooler or more distal erection, and partner discomfort from ring-related rigidity pattern. PDE5 inhibitors produce drug-class side effects ranging from mild (headache, flushing) to serious (severe hypotension with nitrates, rare non-arteritic anterior ischemic optic neuropathy) [20].

How to Use a VED Correctly

Proper technique reduces bruising, improves rigidity, and increases long-term adherence. Apply a water-based lubricant to the penile shaft and the open end of the cylinder to form an airtight seal against the perineum. Begin pumping slowly, pausing after each stroke to allow blood to distribute. Most men reach adequate rigidity in 2 to 3 minutes at 6, 8 pump strokes. Slide the constriction ring from the cylinder base onto the penile shaft before removing the cylinder.

Use only constriction rings that come with or are specified for the device. Improvised rings (rubber bands, cable ties) have caused vascular and nerve injury. Set a 30-minute timer every session.

Men on low-dose aspirin (81 mg) or clopidogrel need to discuss VED use with their prescriber. Petechiae are more common with antiplatelet agents, though serious bleeding is rare. Men on warfarin or direct oral anticoagulants (DOACs) should obtain explicit physician approval before using a constriction ring due to compression-related hematoma risk [3].

Clean the cylinder and ring with mild soap and warm water after each use. Prescription devices carry a manufacturer warranty and are covered by Medicare Part B under HCPCS code A4550 or L7900 depending on supplier, and by many commercial insurers under durable medical equipment (DME) benefits.

Who Should Not Use a VED

Absolute contraindications include men with bleeding disorders (hemophilia A or B, von Willebrand disease Type 3), active anticoagulation with a target INR above 3.0, sickle-cell disease or trait with priapism history, and active Peyronie disease in the inflammatory phase where mechanical stress may worsen plaque formation [3].

Relative contraindications include severe phimosis (prevents cylinder placement), penile skin conditions such as active lichen sclerosus, inability to manually operate the pump due to arthritis or hand weakness (though battery-powered models address this), and a history of priapism, since constriction can prolong episodes.

Men with a penile implant already in place have no indication for a VED; the implant provides mechanical erection directly. Those considering an implant in the future should know that penile length preservation through VED rehabilitation before implantation improves final implant size and patient satisfaction, per a review by Mulhall et al. in Journal of Sexual Medicine (2009) [21].

Comparing Costs: VED vs. Oral ED Medications

A prescription VED typically costs $300, $500 as a one-time purchase, with Medicare Part B covering 80% of the approved amount after deductible for beneficiaries with an ED diagnosis linked to an organic etiology. Generic sildenafil 50 mg tablets are available at $1, $3 per pill at most major pharmacies after patent expiration. Generic tadalafil 5 mg daily runs approximately $20, $40 per month at discount pharmacies with coupons. Brand-name Stendra (avanafil 100 mg) remains significantly more expensive at roughly $60, $80 per tablet because no generic version had received final FDA approval as of early 2025 [17].

Over 12 months, a man taking sildenafil 50 mg three times weekly spends approximately $150, $450 on generic pills. A VED costs more upfront but nothing per use thereafter, making it cost-effective over 12 to 24 months for men who maintain adherence.

Practical Prescribing Guidance: Matching the Treatment to the Patient

The American Urological Association's 2018 Guideline on Erectile Dysfunction (reaffirmed 2021) states: "Clinicians should offer VEDs as a treatment option for men with ED who prefer non-pharmacological therapy, who cannot take PDE5 inhibitors, or who are seeking combination therapy after radical prostatectomy" [22]. That recommendation carries a Moderate Evidence-Strength grade.

For men without contraindications to PDE5 inhibitors who have intact neural signaling, the typical first-line approach is:

• Try sildenafil 50 mg or tadalafil 10 mg on-demand for 4, 6 attempts before assessing response.
• If spontaneity matters more than planning, switch to tadalafil 5 mg daily or avanafil 100 mg.
• If on-demand oral therapy fails after dose optimization (sildenafil 100 mg or tadalafil 20 mg for at least 8 attempts), add a VED before escalating to intracavernosal injections.
• Post-prostatectomy: start VED within 4 weeks of catheter removal, add sildenafil 50 mg nightly as neurological recovery proceeds, per the Raina et al. rehabilitation protocol [2].

Avanafil is a reasonable first choice for men who report that the 30 to 60 minute wait for sildenafil or vardenafil disrupts intimacy. Its 15-minute onset in some patients is the shortest in the drug class and is supported by the VIVUS Phase III data [18].

Vardenafil 10 mg or the Staxyn ODT is an option for men who had partial response to sildenafil and want to try a higher-selectivity agent before moving to tadalafil 20 mg.